Adaptimmune Therapeutics Management

Management criteria checks 3/4

Adaptimmune Therapeutics' CEO is Ad Rawcliffe, appointed in Sep 2019, has a tenure of 4.67 years. total yearly compensation is $2.77M, comprised of 23.4% salary and 76.6% bonuses, including company stock and options. directly owns 0.1% of the company’s shares, worth €293.82K. The average tenure of the management team and the board of directors is 4.4 years and 9.2 years respectively.

Key information

Ad Rawcliffe

Chief executive officer

US$2.8m

Total compensation

CEO salary percentage	23.4%
CEO tenure	4.7yrs
CEO ownership	0.1%
Management average tenure	4.4yrs
Board average tenure	9.2yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Ad Rawcliffe's remuneration changed compared to Adaptimmune Therapeutics's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	US$3m	US$650k	-US$114m
Sep 30 2023	n/a	n/a	-US$95m
Jun 30 2023	n/a	n/a	-US$91m
Mar 31 2023	n/a	n/a	-US$114m
Dec 31 2022	US$3m	US$650k	-US$165m
Sep 30 2022	n/a	n/a	-US$175m
Jun 30 2022	n/a	n/a	-US$176m
Mar 31 2022	n/a	n/a	-US$171m
Dec 31 2021	US$4m	US$617k	-US$158m
Sep 30 2021	n/a	n/a	-US$156m
Jun 30 2021	n/a	n/a	-US$149m
Mar 31 2021	n/a	n/a	-US$140m
Dec 31 2020	US$3m	US$574k	-US$130m
Sep 30 2020	n/a	n/a	-US$123m
Jun 30 2020	n/a	n/a	-US$127m
Mar 31 2020	n/a	n/a	-US$138m
Dec 31 2019	US$2m	US$500k	-US$137m
Sep 30 2019	n/a	n/a	-US$144m
Jun 30 2019	n/a	n/a	-US$99m
Mar 31 2019	n/a	n/a	-US$102m
Dec 31 2018	US$1m	US$457k	-US$96m
Sep 30 2018	n/a	n/a	-US$87m
Jun 30 2018	n/a	n/a	-US$93m
Mar 31 2018	n/a	n/a	-US$69m
Dec 31 2017	US$2m	US$444k	-US$70m

Compensation vs Market: Ad's total compensation ($USD2.77M) is above average for companies of similar size in the German market ($USD993.35K).

Compensation vs Earnings: Ad's compensation has been consistent with company performance over the past year.

CEO

Ad Rawcliffe (51 yo)

4.7yrs

Tenure

US$2,774,041

Compensation

Mr. Adrian G. Rawcliffe, also known as Ad, has been the Chief Executive Officer and Director of Adaptimmune Therapeutics plc since September 1, 2019. He had been the Chief Financial Officer of Adaptimmune...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Adrian G. Rawcliffe	CEO, Principal Accounting Officer & Director	4.7yrs	US$2.77m	0.10% $ 293.8k
Helen Tayton-Martin	Co-Founder & Chief Business & Strategy Officer	no data	US$1.18m	0.12% $ 331.7k
Gavin Hilary Wood	Chief Financial Officer	4.1yrs	US$1.17m	0.0063% $ 17.7k
William Bertrand	Chief Operating Officer	7.2yrs	US$1.22m	0.064% $ 181.4k
Elliot Norry	Chief Medical Officer	4.3yrs	US$1.18m	0.037% $ 104.6k
Joanna Brewer	Chief Scientific Officer	2yrs	no data	0.0049% $ 13.8k
Juli Miller	VP of Corporate Affairs & Investor Relations	no data	no data	no data
Kerry Sharp	Senior VP & General Council	8.6yrs	no data	no data
Dana Lynch	Senior Director of Corporate Communications	no data	no data	no data
John Lunger	Chief Patient Supply Officer	4.8yrs	US$1.72m	0.053% $ 150.5k
Dennis Williams	Senior Vice President of Late Stage Development	4.4yrs	no data	no data
Cintia Piccina	Chief Commercial Officer	less than a year	US$2.19m	0.021% $ 60.1k

4.4yrs

Average Tenure

53yo

Average Age

Experienced Management: 473A's management team is considered experienced (4.4 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Adrian G. Rawcliffe	CEO, Principal Accounting Officer & Director	4.7yrs	US$2.77m	0.10% $ 293.8k
David Mott	Independent Chairman of the Board of Directors	9.3yrs	US$174.83k	0% $ 0
Ali Behbahani	Independent Non-Executive Director	9.3yrs	US$111.54k	0% $ 0
Lawrence Alleva	Independent Non-Executive Director	9.2yrs	US$128.80k	0.0094% $ 26.4k
Malcolm Brenner	Member of the Scientific Advisory Board	no data	no data	no data
Wolf Fridman	Member of the Scientific Advisory Board	no data	no data	no data
John Furey	Independent Non-Executive Director	5.8yrs	US$117.25k	0% $ 0
Stephan Grupp	Member of the Scientific Advisory Board	no data	no data	no data
Michael Dustin	Member of the Scientific Advisory Board	no data	no data	no data
Thomas Gajewski	Member of the Scientific Advisory Board	no data	no data	no data
Andy Sewell	Member of the Scientific Advisory Board	no data	no data	no data
Mario Sznol	Member of the Scientific Advisory Board	no data	no data	no data

9.2yrs

Average Tenure

58.5yo

Average Age

Experienced Board: 473A's board of directors are considered experienced (9.2 years average tenure).

Adaptimmune Therapeutics Management

Management criteria checks 3/4

Key information

Recent management updates

Adaptimmune Therapeutics plc, Annual General Meeting, May 14, 2024

Adaptimmune Therapeutics plc Appoints Cintia Piccina as Chief Commercial Officer, Effective March 18, 2024

Adaptimmune Therapeutics plc Announces Management Changes

Insufficient new directors

Insufficient new directors

Adaptimmune Therapeutics plc Appoints Joanna Brewer as Chief Scientific Officer

Recent updates

Adaptimmune Therapeutics plc to Report Q1, 2024 Results on May 15, 2024

Adaptimmune Therapeutics plc, Annual General Meeting, May 14, 2024

New major risk - Shareholder dilution

Full year 2023 earnings released: US$0.57 loss per share (vs US$1.03 loss in FY 2022)

Adaptimmune Therapeutics plc Appoints Cintia Piccina as Chief Commercial Officer, Effective March 18, 2024

Adaptimmune Therapeutics plc to Report Q4, 2023 Results on Mar 06, 2024

Adaptimmune Therapeutics Regains Nasdaq Compliance with the Minimum Bid Price Requirement Under Nasdaq Listing Rule 5450(a)(1)

Adaptimmune Therapeutics plc Announces U.S. FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review

Adaptimmune Therapeutics plc Completes Submission of Rolling Biologics License Application to U.S. FDA for Afami-Cel for the Treatment of Advanced Synovial Sarcoma

New minor risk - Market cap size

Third quarter 2023 earnings released: US$0.20 loss per share (vs US$0.25 loss in 3Q 2022)

Adaptimmune Therapeutics plc to Report Q3, 2023 Results on Nov 08, 2023

Adaptimmune Therapeutics Receives Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement of its American Depositary Shares

New minor risk - Shareholder dilution

Second quarter 2023 earnings released: US$0.12 loss per share (vs US$0.28 loss in 2Q 2022)

Adaptimmune Therapeutics plc to Report Q2, 2023 Results on Aug 09, 2023

Adaptimmune Therapeutics plc (NasdaqGS:ADAP) completed the acquisition of TCR2 Therapeutics Inc. (NasdaqGS:TCRR) from a group of shareholders.

First quarter 2023 earnings released: EPS: US$0.006 (vs US$0.32 loss in 1Q 2022)

Full year 2022 earnings released: US$1.03 loss per share (vs US$1.02 loss in FY 2021)

Adaptimmune Therapeutics plc Announces Management Changes

Insufficient new directors

Third quarter 2022 earnings released: US$0.25 loss per share (vs US$0.27 loss in 3Q 2021)

Adaptimmune Therapeutics plc to Report Q3, 2022 Results on Nov 08, 2022

Second quarter 2022 earnings released: US$0.28 loss per share (vs US$0.25 loss in 2Q 2021)

Adaptimmune Therapeutics plc to Report Q2, 2022 Results on Aug 04, 2022

Insufficient new directors

Adaptimmune Therapeutics plc Present Preclinical Proof-Of-Concept Data from Its Second Next-Generation SPEAR T-cell

Adaptimmune Therapeutics plc Appoints Joanna Brewer as Chief Scientific Officer

Adaptimmune Therapeutics plc, Annual General Meeting, May 25, 2022

Adaptimmune Therapeutics plc Presents MAGE-A4 Expression Data from Its Screening Protocol At American Association for Cancer Research

Adaptimmune Therapeutics plc announced delayed annual 10-K filing

Key Executive recently sold €54k worth of stock

Third quarter 2021 earnings released: US$0.27 loss per share (vs US$0.23 loss in 3Q 2020)

Adaptimmune Therapeutics plc Announces Clinical Responses Across Five Solid Tumor Indications with an Overall Response Rate of 36% and Promising Early Durability from its Next-Generation Surpass Trial

Second quarter 2021 earnings released: US$0.25 loss per share (vs US$0.22 loss in 2Q 2020)

Adaptimmune Therapeutics plc Reports Preclinical Data From its HiT Targeting Mesothelin, Being Co-Developed With Astellas, During a Poster Presentation at the American Society for Cell and Gene Therapy (ASGCT) Meeting

First quarter 2021 earnings released: US$0.24 loss per share (vs US$0.23 loss in 1Q 2020)

Adaptimmune Therapeutics plc to Present First Preclinical Data from its HLA-independent TCR Platform at ASGCT

Full year 2020 earnings released: US$0.91 loss per share (vs US$1.31 loss in FY 2019)

Revenue beats expectations

Adaptimmune Therapeutics plc to Report Q4, 2020 Results on Feb 25, 2021

New 90-day high: €5.10

Adaptimmune Therapeutics plc Promotes Elliot Norry, Chief Medical Officer, to Executive Team Effective from January 1, 2021

New 90-day low: €3.50

New 90-day low: €3.68

Third quarter 2020 earnings released: US$0.23 loss per share

Revenue beats expectations

Adaptimmune Therapeutics plc Presents Initial Tumor Reductions from Early Dose Cohorts of Surpass Trial, At SITC

Third quarter 2020 earnings released: US$0.34 loss per share

Revenue beats expectations

New 90-day low: €5.15

New 90-day high: €8.90

Adaptimmune Therapeutics plc to Report Q2, 2020 Results on Aug 06, 2020

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age